Global Manufacturing Capacity Flamma's fully integrated CDMO platform with three facilities across Italy, the USA, and China, offering comprehensive Small Molecule API manufacturing from preclinical to commercial scale, presents an opportunity to support multinational pharmaceutical companies seeking reliable cross-continent supply chains.

Industry Recognition Receiving the 2025 CDMO Leadership Award and recognition as Europe’s top CMO/CDMO in 2022 positions Flamma as a trusted partner in the pharmaceutical manufacturing industry, making it an attractive prospect for companies prioritizing proven excellence and quality in their supply partnerships.

Strong Technical Expertise Specializing in high-value chiral materials, amino acids for peptide drugs, and advanced intermediates, Flamma offers unique developmental and manufacturing capabilities that cater to complex drug molecules, presenting opportunities to collaborate on innovative pharmaceutical projects.

Growth and Expansion Recent investments such as expanding Italy operations and acquiring additional API sites showcase Flamma’s growth trajectory, indicating capacity to handle increasing client demand and providing a solid foundation for onboarding new pharmaceutical collaborations.

Market Positioning As a family-owned, award-winning CDMO with a focus on small molecule APIs, Flamma’s competitive edge and reputation for quality and stability make it a compelling partner for biotechs and pharma companies seeking dependable manufacturing partners with a global footprint.